Novartis plans to build a new radioligand therapy (RLT) manufacturing facility in Denton, Texas, expanding its U.S. production network as demand for the cancer treatment grows.

The Basel-based drugmaker said the 46,000-square-foot site is expected to be operational in 2028.

The Denton facility will be Novartis’ fifth RLT manufacturing site in the United States and its first in Texas. Construction is scheduled to begin this year. The company said the site will support patients across the southern U.S. and add capacity as radioligand therapies move into earlier lines of treatment and additional tumor types.
Novartis said the facility will create jobs in bioengineering, advanced manufacturing, quality and operations. The project is part of a previously announced $23 billion investment in U.S. operations.

“RLT has the potential to revolutionize cancer care,” said Vas Narasimhan, CEO of Novartis. “The addition of our fifth RLT manufacturing site in the U.S. strengthens our ability to meet growing demand, building the capabilities needed to deliver these next-generation treatments with the speed and precision they require.”

Texas Governor Greg Abbott said the investment would establish Novartis’ first cancer therapy manufacturing facility in the state, and add jobs tied to biotech and manufacturing.

Radioligand therapies are custom-made and time-sensitive, requiring coordinated manufacturing and delivery. Novartis said its U.S. network administers more than 99% of doses on the planned treatment day. Existing sites are located in New Jersey, Indiana and California, with another facility recently announced in Florida.

The company is studying RLTs across several tumor types, including prostate, breast, colon, lung, brain and pancreatic cancers. As development programs advance, manufacturing scale and geographic proximity to treatment centers have become central operational considerations for drugmakers in the space.

U.S. Healthcare Homepage